Startseite The crystal structure of tris(1-ethylimidazole-κ1N)-(sulfato-κ2O,O′)vanadium(IV), C15H24N6O5SV
Artikel Open Access

The crystal structure of tris(1-ethylimidazole-κ1N)-(sulfato-κ2O,O′)vanadium(IV), C15H24N6O5SV

  • Yi-Ru Fu , Jian Luan und Xiao-Jie Wang ORCID logo EMAIL logo
Veröffentlicht/Copyright: 9. April 2020

Abstract

C15H24N6O5SV, monoclinic, P21/c (no. 14), a = 16.0059 Å, b = 9.1008 Å, c = 14.2686 Å, β = 100.352°, V = 2044.6(2) Å3, Z = 4, Rgt(F) = 0.0400, wRref(F2) = 0.0852, T = 173(2) K.

CCDC no.: 1989326

The complex title structure is shown in the figure. Table 1 contains crystallographic data and Table 2 contains the list of the atoms including atomic coordinates and displacement parameters.

Table 1:

Data collection and handling.

Crystal:Blue plate
Size:0.19 × 0.16 × 0.07 mm
Wavelength:Mo Kα radiation (0.71073 Å)
μ:0.63 mm−1
Diffractometer, scan mode:CCD, φ and ω
θmax, completeness:25.3°, 99%
N(hkl)measured, N(hkl)unique, Rint:11434, 3692, 0.063
Criterion for Iobs, N(hkl)gt:Iobs > 2 σ(Iobs), 2699
N(param)refined:256
Programs:Bruker [1], SHELX [2], Olex2 [3]
Table 2:

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).

AtomxyzUiso*/Ueq
C10.64695(19)0.3047(3)0.3291(2)0.0198(7)
H10.6884290.2753930.2929030.024*
C20.5264(2)0.3790(3)0.3655(2)0.0257(7)
H20.4693090.4109150.3610460.031*
C30.58492(19)0.3600(3)0.4466(2)0.0235(7)
H30.5751050.3762680.5095410.028*
C40.5290(2)0.3381(4)0.1892(2)0.0293(8)
H4A0.4847740.2608720.1783960.035*
H4B0.5734890.3116820.1520890.035*
C50.4900(2)0.4836(4)0.1540(2)0.0452(10)
H5A0.4444710.5082900.1889070.068*
H5B0.4666380.4764250.0858220.068*
H5C0.5336450.5603110.1645140.068*
C60.74230(19)−0.0441(3)0.4228(2)0.0243(7)
H60.759494−0.0129380.3655970.029*
C70.6967(2)−0.1823(4)0.5275(2)0.0333(8)
H70.676364−0.2640230.5582840.040*
C80.7129(2)−0.0469(4)0.5641(2)0.0283(8)
H80.705379−0.0163250.6256750.034*
C90.7073(2)−0.3020(4)0.3686(3)0.0440(10)
H9A0.678455−0.3855690.3937760.053*
H9B0.671101−0.2697820.3083670.053*
C100.7896(3)−0.3522(4)0.3482(3)0.0508(11)
H10A0.817870−0.2707030.3216850.076*
H10B0.780307−0.4330010.3020550.076*
H10C0.825276−0.3864430.4072190.076*
C110.8997(2)0.1735(4)0.7014(2)0.0262(7)
H110.8592450.1986460.7400120.031*
C121.0167(2)0.0960(4)0.6582(2)0.0309(8)
H121.0720750.0576590.6595530.037*
C130.9616(2)0.1415(4)0.5806(2)0.0286(8)
H130.9720640.1402140.5171540.034*
C141.0140(2)0.0929(5)0.8359(2)0.0440(10)
H14A1.046147−0.0005990.8430430.053*
H14B0.9678870.0854820.8735340.053*
C151.0721(3)0.2170(5)0.8733(3)0.0596(13)
H15A1.1183760.2230560.8368610.089*
H15B1.0957090.1997540.9406100.089*
H15C1.0401190.3094280.8667710.089*
N10.66062(15)0.3136(3)0.42325(16)0.0175(5)
N20.56687(16)0.3426(3)0.29145(17)0.0216(6)
N30.74200(15)0.0407(3)0.49793(17)0.0206(6)
N40.71516(18)−0.1797(3)0.43794(19)0.0285(7)
N50.88789(16)0.1901(3)0.60755(17)0.0211(6)
N60.97685(17)0.1161(3)0.73432(18)0.0293(7)
O10.83011(13)0.2731(2)0.42317(14)0.0237(5)
O20.78286(13)0.4676(2)0.56484(13)0.0204(5)
O30.71898(12)0.2765(2)0.63494(13)0.0191(5)
O40.80374(13)0.4561(2)0.73786(14)0.0274(5)
O50.66665(13)0.5260(2)0.64964(15)0.0271(5)
S10.74209(5)0.43673(8)0.65095(5)0.01873(18)
V10.77923(3)0.26022(6)0.50944(3)0.01657(13)

Source of material

VOSO4⋅2 H2O (0.199 g, 1 mmol) in 1-ethylimidazole (6 mL) was sealed in a 20 mL vial, which was heated to 90° under autogenously pressure for 72 h. Yield: 60% based on V. Anal. Calcd. for C15H24N6O5SV (%): C, 39.91; H, 5.36; N, 18.62. Found: C, 39.78; H, 5.51; N, 18.49.

Experimental details

The structure was solved by direct methods with the SHELXS program. All H-atoms were positioned with idealized geometry and refined isotropic (Uiso(H) = 1.2Ueq(C)), using a riding model with C(imodazole)—H = 0.950 Å, C(methylene)—H = 0.99 Å and C(methyl)—H = 0.98 Å, respectively.

Comment

The range of potential applications of vanadium complexes range from catalysis to bioactivity [4], [5], [6], [7], [8], [9], [10]. The design and synthesis of vanadium complexes will be very meaningful. In this text, we describe the synthesis of an interesting vanadium complex by a simple solvothermal reaction.

The central vanadium atom adopts a ‘4 + 1 + 1’ geometry formed by three N atoms from1-eIM, two bridging oxygen Ob from sulfate and one terminal oxygen Ot with the V—O and V—N bonds within the range of 1.597–2.186 Å and 2.082–2.125 Å, respectively [11]. The sulfate ligand is coordinated in a chelating bidentate mode with the S—O bonds within 1.448–1.518 Å. Although the central vanadium possesses distorted octahedral coordination geometry which is same to the previous reports in the similar system [12]. But in the previous reports, the four coordinated equatorial atoms are N atoms from 1-eIM. It is noteworthy that the 1-eIM plays a dual function as solvent and ligands.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (no. 21401111) and the Natural Science Foundation of Liaoning Shihua University (2019XJJL-019).

References

1. Bruker. SAINTv8.37A. Bruker AXS Inc, Madison, WI, USA (2015).Suche in Google Scholar

2. Sheldrick, G. M.: Crystal structure refinement with SHELXL. Acta Crystallogr. C71 (2015) 3–8.10.1107/S2053229614024218Suche in Google Scholar PubMed PubMed Central

3. Dolomanov, O. V.; Bourhis, L. J.; Gildea, R. J.; Howard, J. A. K.; Puschmann, H.: OLEX2: a complete structure solution, refinement and analysis program. J. Appl. Crysallogr. 42 (2009) 339–341.10.1107/S0021889808042726Suche in Google Scholar

4. Barthelet, K.; Riou, D.; Ferey, G.: [VIII(H2O)]3O(O2CC6H4CO2)3⋅(Cl, 9H2O) (MIL-59): a rare example of vanadocarboxylate with a magnetically frustrated three-dimensional hybrid framework. Chem. Commun. 14 (2002) 1492–1493.10.1039/b202749fSuche in Google Scholar PubMed

5. Laye, R. H.; Wei, Q.; Mason, P. V.; Shanmugam, M.; Teat, S. J.; Brechin, E. K.; Collison, D.; McInnes, E. J. L.: A highly reduced vanadium(III/IV) polyoxovanadate comprising an octavanadyl square-prism surrounding a dimetallic vanadium(III) fragment. J. Am. Chem. Soc. 128 (2006) 9020–9021.10.1021/ja062723+Suche in Google Scholar PubMed

6. Hu, X. K.; Wang, H.; Huang, B.; Li, N.; Hu, K. H.; Wu, B. L.; Xiao, Z. C.; Wei, Y. H.; Wu, P. F.: A new scheme for rational design and synthesis of polyoxovanadate hybrids with high antitumor activities. J. Inorg. Biochem. 193 (2019) 130–132.10.1016/j.jinorgbio.2019.01.013Suche in Google Scholar PubMed

7. Steens, N.; Ramadan, A. M.; Absillis, G.; Parac-Vogt, T. N.: Hydrolytic cleavage of DNA-model substrates promoted by polyoxovanadates. Dalton Trans. 39 (2010) 585–592.10.1039/B913471ASuche in Google Scholar PubMed

8. Boulmier, A.; Feng, X. X.; Oms, O.; Mialane, P.; Riviere, E.; Shin, C. J.; Yao, J. Q.; Kubo, T.; Furuta, T.; Oldfield, E.; Dolbecq, A.: Anticancer activity of polyoxometalate-bisphosphonate complexes: synthesis, characterization, in vitro and in vivo results. Inorg. Chem. 56 (2017) 7558–7565.10.1021/acs.inorgchem.7b01114Suche in Google Scholar PubMed PubMed Central

9. Dankhoff, K.; Ahmad, A.; Weber, B.; Biersack, B.; Schobert, R.: Anticancer properties of a new non-oxido vanadium(IV) complex with a catechol-modified 3,3′-diindolylmethane ligand. J. Inorg. Biochem. 194 (2019) 1–6.10.1016/j.jinorgbio.2019.02.005Suche in Google Scholar PubMed

10. Wang, L. J.; Fan, H. T.; Du, C. J.; Xing, X. J.; Zhao, Y. Y.; Chen, B. K.; Wang, L. Y.: Synthesis, structure and properties of a co-crystallized complex based on polyoxovanadate [VIV12VV6O42]6− and a mononuclear vanadium complex [VON(CH2CH2O)3]. Inorg. Chem. Commun. 63 (2016) 39–41.10.1002/chin.201610220Suche in Google Scholar

11. Biswal, D.; Pramanik, N. R.; Chakrabarti, S.; Drew, M. G. B.; Acharya, K.; Chandra, S.: Syntheses, crystal structures, DFT calculations, protein interaction and anticancer activities of water soluble dipicolinic acid-imidazole based oxidovanadium(iv) complexes. Dalton Trans. 46 (2017) 16682–16702.10.1039/C7DT02903ASuche in Google Scholar PubMed

12. Chen, B. K.; Huang, X. Q.; Wang, B.; Lin, Z. G.; Hu, J. F.; Chi, Y. N.; Hu, C. W.: Three new imidazole-functionalized hexanuclear oxidovanadium clusters with exceptional catalytic oxidation properties for alcohols. Chem. Eur. J. 19 (2013) 4408–4413.10.1002/chem.201203854Suche in Google Scholar PubMed

Received: 2020-02-17
Accepted: 2020-03-10
Published Online: 2020-04-09
Published in Print: 2020-06-25

©2020 Yi-Ru Fu et al., published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution 4.0 Public License.

Artikel in diesem Heft

  1. Frontmatter
  2. Crystal structure of bis [1-(phenylsulfonyl)-2-(1-(pyrazin-2-yl)ethylidene)hydrazin-1-ido-κ3N,N′,O]cobalt(II), C24H22N8O4S2Co
  3. The crystal structure of 1,3-bis(4-(methoxycarbonyl)benzyl)-2-methyl-1H-benzo[d]imidazol-3-ium bromide, C26H25BrN2O4
  4. Crystal structure of {tris((1H-benzo[d]imidazol-2-yl)methyl)amine-κ4N,N′,N′′,N′′′}-(nitrito-κ2O,O′)nickel(II) perchlorate – ethanol (1/1), C26H27ClN8NiO7
  5. Crystal structure of catena-poly[aqua[(μ2-4,5-dicarboxylato-2-(2-carboxylatophenyl)imidazol-1-ido-κ4N,O,O′:N′)](μ2-4,4′-bipyridine-κ2N:N′)dicopper(II)], C22H14Cu2N4O7
  6. Crystal structure of chlorido-tris(4-methylbenzyl-κC)-(triphenylarsine oxide-κO)tin(IV), C42H42AsClOSn
  7. The crystal structure of 4,4′-bipyridinium bis(3-carboxy-2-nitrobenzoate) tetrahydrate, C13H13N2O8
  8. Crystal structure of 1-(3-chlorophenyl)-4-(4-(((2,3-dihydro-1H-inden-5-yl)oxy)methyl)phenethyl)piperazine, C28H31ClN2O
  9. Crystal structure of catena-poly[diaqua-bis(μ2-5,5′-(1H-imidazole-4,5-diyl)bis(tetrazol-2-ido)-κ4N,N′:N′′,N′′′)magnesium], C10H8N20O2Mg
  10. The crystal structure of (E)-2-((2-hydroxy-4-ethoxybenzylidene)amino)-2-methylpropane-1,3-diol monohydrate, C13H21NO5
  11. Crystal structure of catena-poly[diaqua-(μ2-bipyridine-κ2N:N′)-bis(3,5-dichloroisonicotinato-κO)cadmium(II)] dihydrate, C22H20CdCl4N4O8
  12. The crystal structure of 4-(4-chlorophenyl)cyclohexane-1-carboxylic acid, C13H15ClO2
  13. Redetermination of the crystal structure of yttrium(III) trinitrate(V) pentahydrate, Y(NO3)3 ⋅ 5 H2O, H10N3O14Y
  14. Crystal structure of catena-poly[di-μ2-chlorido-1,10-phenanthroline-κ2N,N′-cadmium(II)], C12H8Cl2CdN2
  15. Crystal structure of 4-((2-methyl-6-(trifluoromethyl)pyrimidin-4-yl)oxy)benzoic acid, C13H9F3N2O3
  16. Crystal structure of 3-acetyl-4-hydroxybenzoic acid, C18H16O8
  17. Crystal structure of bis(N,2-bis(4-ethoxybenzylidene)hydrazine-1-carbohydrazonothioato-κ2N,S)nickel(II) — N,N-dimethylformamide (1/2), C44H56N10S2O6Ni
  18. The crystal structure of 5-chloro-4,6-dimethoxypyrimidin-2-amine, C6H8ClN3O2
  19. Crystal structure of poly[aqua-(μ4-benzene-1,2,4,5-tetracarboxylato-κ4O,O′,O′′,O′′′)bis(μ2-1-(4-(1H-imidazol-1-yl)benzyl)-1H-1,2,4-triazole-κ2N:N)dinickel(II)], NiC17H14N5O5
  20. Crystal structure of poly[aqua(5-dimethylamino)naphthalene-1-sulfonato-κ2N:O)(μ2-4,4′-bipyridyl -κ2N:N′)silver(I)], C44H44Ag2N6O8S2
  21. Crystal structure of 1-[3-(trifluoromethyl)cinnamoyl]-3-(pyridin-2-yl-κN)pyrazole-κ2N-bis(2-phenylpyridinato-k2C,N)iridium(III) hexafluorophosphate complex, [C40H28F3IrN5O]PF6
  22. Crystal structure of catena-poly[aqua(μ6-piperazine-1,4-bisethanesulfonato-κ6N:N′:O:O′:O′′:O′′′)(μ2-pyrazinyl-κ2N:N′)disilver(I)sesquihydrate], C12H30Ag2N4O11S2
  23. Crystal structure of (E)-1-(2-nitrophenyl)-N-(o-tolyl)methanimine, C14H12N2O2
  24. Crystal structure of 4′-amino-3′,5′-diisopropyl-(1,1′-biphenyl)-4-carbonitrile, C19H22N2
  25. The crystal structure of poly[bis(N,N-dimethylformamide-κ1O)-tetrakis(μ2-cyanido-κ2C:N)dinickel(II)], C10H14N6O2Ni2
  26. Crystal structure of rac-trans-N,N′-bis(3-bromo-5-chlorosalicylidene)-1,2-cyclohexanediamine, C20H18Br2Cl2N2O2
  27. Crystal structure of rac-trans-N,N′-bis(3,5-dibromosalicylidene)-1,2-cyclohexanediamine, C20H18Br4N2O2
  28. The crystal structure of (dichromato-κ2O,O′)bis(1,10-phenanthroline-κ2N,N′)nickel(II), C12H16N4O7Cr2Ni
  29. The crystal structure of 3-((1R,2S)-1-methylpyrrolidin-1-ium-2-yl)pyridin-1-ium tetrachloridozincate(II) monohydrate, C10H18Cl4ZnN2O
  30. Crystal structure of bis(μ2-azido-k2N,N)-bis(2-amino-1-(N-(3-bromosalicylaldiminato))ethane)-dicopper(II), C20H18Br4N2O2
  31. Crystal structure of (η6-1-methyl-4-isopropylbenzene)-[5-bromo-2-(2-pyridyl)phenyl-κ2C,N]-chloro-ruthenium(II), C21H21BrClNRu
  32. Crystal structure of N-(methyl(oxo)(1-(6-(trifluoromethyl)pyridin-3-yl)ethyl)-λ6-sulfanylidene)cyanamide, C10H10F3N3OS
  33. Crystal structure of 6,6′-((cyclohexane-1,2-diylbis(azanylylidene))bis(methanylylidene))bis(2-bromo-4-chlorophenolato-κ4N,N′,O,O′)nickel(II), C20H16Br2Cl2NiN2O2
  34. Redetermination of the crystal structure of catena-poly[aqua-(1,10-phenanthroline-κ2N,N′)-(μ2-tetraoxidomolybdato(VI)-κ2O:O′)manganese(II) monohydrate, C12H12N2O6MoMn
  35. The crystal structure tetrakis(μ2-o-chlorobenzoato-κ2O:O′)-bis(methanol-κ1O)dirhodium(II), C30H24Cl4O10Rh2
  36. Crystal structure of bis(2,3-diphenyltetrazolidine-5-thione-κ1S)-(nitrato-κ1O)-(nitrato-κ2O,O′)lead(II), C26H20N10O6S2Pb
  37. Crystal structure of bis(3-bromo-N-(1-(3-methylpyrazin-2-yl)ethylidene)benzohydrazonato-κ3O,N,N′)cadmium(II) hemihydrate, C28H25N8O2.5Br2Cd
  38. Crystal structure of catena-poly[tetrakis(μ2-trifluoroacetato-κ2O:O′)(μ2-2,5-dimethylpyrazine-κ2N,N′)dicopper(II)], C7H4CuF6NO4
  39. The crystal structure of catena-poly[bis[3-azoniapentane-1,5-diammonium][bis(μ4-oxo)-tetrakis(μ3-oxo)-heptakis(μ2-oxo)-tetradecaoxo-octa-molybdenum] dihydrate], (C8H36N6O29Mo8)n
  40. Crystal structure of tetraaqua-bis(2-((3,5,6-trichloropyridin-2-yl)oxy)acetato-κO)-nickel(II)—diaqua-bis(2-((3,5,6-trichloropyridin-2-yl)oxy)acetato-nickel(II), C28H24Cl12N4Ni2O18
  41. The crystal structure of bis(2-hydroxypyrimidinium) pentachloridobismuthate(III), (C4N2H5O)2BiCl5
  42. The crystal structure of catena-poly[(μ2-4,4′-dipyridine-κ2N,N′)-bis(3,5,6-trichloropyridine-2-oxyacetato-κO)-bis(ethanol-κO)nickel(II)], C28H26Cl6N4NiO8
  43. Crystal structure and anti-inflammatory activity of (3E,5E)-1-((4-chlorophenyl)sulfonyl)-3,5-bis(4-fluorobenzylidene)piperidin-4-one-dichloromethane (1/1), C26H20Cl3F2NO3S
  44. The crystal structure of 5-bromopicolinic acid monohydrate, C6H6BrNO3
  45. The crystal structure of 2-(3-(4-bromophenyl)-5-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)-8H-indeno[1,2-d]thiazole, C25H17BrFN3S
  46. The crystal structure of catena-poly[(μ2-2-((3-bromo-2-oxidobenzylidene)amino)acetato-κ4O,N,O′:O′′)-(dimethylformamide-κ1O)]zinc(II), C12H13N2O4BrZn
  47. Crystal structure of aqua-azido-κ1N-(6,6′-((propane-1,3-diylbis(azanylylidene))bis(methanylylidene))bis(3-bromophenolato)-κ4N,N′,O,O′iron(III), C17H16Br2FeN5O3
  48. The crystal structure of tris(1-ethylimidazole-κ1N)-(sulfato-κ2O,O′)vanadium(IV), C15H24N6O5SV
  49. Crystal structure of (E)-3-methoxy-N′-(1-(pyridin-2-yl)ethylidene)benzohydrazide, C15H15N3O2
  50. Crystal structure of dichloro-bis-(1-butyl-1H-benzo[d]imidazole)-nickel(II), C22H28Cl2N4Ni
  51. The crystal structure of 2-(2,3-dimethoxyphenyl)-3-hydroxy-4H-chromen-4-one, C17H14O5
  52. The crystal structure of 5-(2-(4-fluorophenyl)hydrazono)-4-methyl-2-((3-(5-methyl-1-(4-methylphenyl)-1H-1,2,3-triazol-4-yl)-1-phenyl-1H-pyrazol-4-yl)methylene) hydrazono)-2,5-dihydrothiazole dimethylformamide monosolvate, C30H25FN10S⋅C3H7NO
  53. The crystal structure of 1,8-bis(pyridin-4-ylethynyl)anthracene-1,2,4,5-tetrafluoro-3,6-diiodobenzene (2/1), C62H32F4I2N4
  54. The crystal structure of 3,6-di-tert-butyl-1,8-diiodo-9-methyl-9H-carbazole, C21H25I2N
  55. The crystal structure of 8-((4-chlorophenylamino)methylene)-6,10-dioxaspiro[4.5]decane-7,9-dione, C15H14ClNO4
  56. The crystal structure of catena-poly[oktaaqua-bis(μ2-4,4′-ethene-1,2-diyldipyridine-κ2N:N′)-(μ2-3,3′-(1-oxidodiazene-1,2-diyl)diphthalato-κ2O:O′)dicobalt(II)] dihydrate, C28H36N4O19Co2
  57. Crystal structure of (E)-1-(2-cyano-3-oxo-1-phenylprop-1-en-1-yl)-3,7-diphenylindolizine-6-carbonitrile, C31H19N3O
  58. Crystal structure of 1,1′-bis(diphenylphosphino)ferrocene-(1,1′-bis(diphenylphosphino)ferrocene-κ2P,P′)-(O-isobutyl sulfurodithioito-κ2S,S′)copper(I), C39H37CuFeOP2S2
  59. Crystal structure of poly[(5-bimethylamino-1-naphthalenesulfonato-κO)-(μ3-hexamethylenetetramino-κ3N:N′:N′′)silver(I)] dihydrate, C36H52Ag2N10O8S2
  60. Crystal structure of poly[μ2-diaqua-(μ2-2-amino-4,5-dicyano-κ2N:N′-imidazol-1-ide)sodium(I)], C5H6N5O2Na
  61. Crystal structure of (1,3-propanediamine-κ2N,N′)(N-(3-aminopropyl)-α-methyl aspartato-κ4N,N′,O,O′)cobalt(III) chloride, C11H24ClCoN4O4
  62. Crystal structure and anti-inflammatory activity of (3E,5E)-3,5-bis(4-fluorobenzylidene)-1-((4-fluorophenyl)sulfonyl)piperidin-4-one-dichloromethane (1/1), C26H20Cl2F3NO3S
  63. Crystal structure of (S)-(+)-1-cyclohexylethylaminium chloride, C8H18NCl
  64. The crystal structure of tris(nitrato-κ2O,O′)-bis(4,4,5,5-tetramethyl-2-(o-pyridyl)imidazoline-1-oxyl 3-oxide-κ2N,O)yttrium(III), C24H32N9O13Y
  65. Hydrogen bonding versus packing effects in the crystal structure of 3-((1R,2S)-1-methylpyrrolidin-1-ium-2-yl)pyridin-1-ium tetraiodidozincate(II), C10H16I4ZnN2
  66. Dimerization of 2-[(2-((2-aminophenyl)thio)phenyl)amino]-cyclohepta-2,4,6-trien-1-one through hydrogen bonding, C19H16N2OS
  67. Crystal structure of 1-(4-chloro-phenyl)-7-ethoxyl-6,8-difluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid, C18H12ClF2NO4
  68. Crystal structure of 7-ethoxy-6,8-difluoro-4-oxo-1-pyridin-2-ylmethyl-1,4-dihydro-quinoline-3-carboxylic acid, C18H14F2N2O4
  69. Crystal structure of octahydro-7aR,8′R-dimethylspiro[isobenzofuran-4(1H), 4′ (3′H)-[1H-7,9a]methanocyclohepta[c]pyran]-1′,3, 9′ (3aH,4′aH)-trione, C20H26O5
  70. Crystal structure of bis(5-ethoxy-2-(((1-hydroxy-2-methyl-3-oxidopropan-2-yl)imino)methyl)phenolato-κ3N,O,O’)manganese(IV) – methanol (1/1), C27H38MnN2O9
  71. Crystal structure of 8a,8a′′-oxybis(8aH-8,9-dioxa-3a1λ4-aza-8aλ4-borabenzo[fg]tetracene), C34H22B2N2O5
  72. Crystal structure of bromido-triphenyl-(triphenylarsine oxide-κO)tin(IV), C36H30AsBrOSn
  73. Crystal structure of catena-poly[chlorido-(μ2-formato-κ2O:O′)-(1,10-phenathroline-κ2N,N′)copper(II)], C26H18Cl2Cu2N4O4
  74. The crystal structure of poly[(μ10-5-carboxyisophthalato-κ10O)disodium], C9H4Na2O6
  75. The crystal structure of 3,5-difluoroisonicotinic acid, C6H3F2NO2
  76. The crystal structure of ethyl-1-(N-(adamantan-1-yl)-carbamothioyl)piperidine-4-carboxylate, C19H30N2O2S
  77. Crystal structure of 5-methyl-3-phenyl-1-tosyl-1,2,3,4-tetrahydropyridine, C19H21NO2S
  78. Crystal structure of bis((3-chlorosalicylidene)-ethylenediaminato-κ4N,N′,O,O′)nickel (II), C16H12Cl2NiN2O2
  79. Crystal structure of (E)-N′-(2-chloro-6-hydroxybenzylidene)-4-hydroxybenzohydrazide — dihydrofuran-2(3H)-one (1/1), C18H17ClN2O5
  80. Crystal structure of bis((3-bromosalicylidene)-ethylenediaminato-κ4N,N′,O,O′) nickel (II), C16H12Br2NiN2O2
  81. Crystal structure of trimethylsulfoxonium tetrachloridocobaltate(II) [(CH3)3SO]2CoCl4
Heruntergeladen am 11.11.2025 von https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2020-0095/html?lang=de
Button zum nach oben scrollen